MS Views and News, empowers those affected by Multiple Sclerosis (MS) with educational information, resources and services. Visit Our Youtube Channel: https://Youtube.com/MSViewsandNews
Monday, April 29, 2019
New Genentech Data at the 2019 AAN Annual Meeting Showcase Breadth and Promise of Neuroscience Portfolio
Risdiplam data from Part 1 of pivotal FIREFISH study show infants with Type 1 spinal muscular atrophy achieve key motor milestones and improved survival after one year of treatment
New analyses in relapsing and primary progressive multiple sclerosis suggest that higher OCREVUS® (ocrelizumab) exposure and lower B-cell levels are important for control of disability progression
Satralizumab significantly reduces the risk of relapse in neuromyelitis optica spectrum disorder in pivotal SAkuraSky study
New data in Huntington’s disease support dose selection for Phase III trial and provide insight on mutant huntingtin protein (mHTT) reduction
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data for its approved and investigational medicines for the treatment of neurological conditions will be presented at the 71st American Academy of Neurology (AAN) Annual Meeting from May 4-10 in Philadelphia, PA. Presentations include data from a pivotal study for risdiplam in spinal muscular atrophy (SMA), which has the potential to become the first oral treatment for this community. New research for OCREVUS® (ocrelizumab) in relapsing and primary progressive multiple sclerosis shows that its effect on reducing the risk of disability progression is associated with higher exposure and lower B-cell levels. Additional OCREVUS data demonstrate the importance of earlier treatment. New data for investigational medicines in neuromyelitis optica spectrum disorder (NMOSD), Huntington’s disease (HD), Alzheimer’s disease (AD) and Duchenne muscular dystrophy (DMD) will also be shared.
No comments:
Post a Comment
Thank You for leaving a comment.
Attempts to redirect viewers of this blog to another website and / or any marketing, will be removed.
Note: Only a member of this blog may post a comment.